BioSyent to Release Q3 2025 Earnings on November 20 Under CEO René Goehrum
BioSyent Inc., a TSX Venture Exchange-listed specialty pharmaceutical company under the symbol 'RX', will unveil its financial results for the third quarter and year-to-date 2025 on November 20, 2025. The presentation by President and CEO René Goehrum will be accessible on the company's website upon release.
BioSyent, a profitable and growth-oriented company, focuses on improving patients' lives through in-licensing or acquiring innovative pharmaceutical and healthcare products with proven track records.
As of November 13, 2025, BioSyent has 11,262,282 common shares outstanding. Notably, Amplimedical Holdings Ltd., controlled by Shim Sang-pil, holds the largest shareholding in BioSyent, owning approximately 28.6% of outstanding shares.
BioSyent Inc. will disclose its financial results for the three months and nine months ended September 30, 2025, after market hours on November 20, 2025. The presentation by President and CEO René Goehrum will be available on the company's website following the release.
